Do not administer concomitantly w/ MAOIs or w/in 2 wk of cessation of MAOIs. Increased incidence of serotonin-associated effects w/ other serotonergic active substances (eg, L-tryptophan, triptans, tramadol, linezolid, methylene blue, SSRIs, venlafaxine, lithium, St. John's Wort). May increase the sedating properties of benzodiazepines & other sedatives. May increased CNS depressant effect of alcohol. Increased INR w/ warfarin. Increased risk of QT prolongation &/or ventricular arrhythmias w/ concomitant use of medicines which prolong the QTc interval. Decreased plasma conc w/ carbamazepine & phenytoin (CYP3A4 inducers). Increased Cmax
& AUC w/ potent CYP3A4 inhibitors (eg, HIV PIs, azole antifungals, erythromycin, cimetidine or nefazodone).